Jardiance (empagliflozin tablet, film coated) is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure; to reduce the risk of sustained decline in eGFR, end-stage kidney disease, ...
Dosing Considerations Limitations of use Not indicated for treatment of type 1 diabetes or diabetic ketoacidosis Not recommended for use to improve glycemic control in adults with type 2 diabetes mellitus with an eGFR <30 mL/min/1.73 m2
a history of severe allergic or skin reaction after taking empagliflozin or linagliptin; or diabetic ketoacidosis (call your doctor for treatment).Tell your doctor if you have ever had:liver or kidney disease; a bladder infection or urination problems; a pancreas disorder; heart failure; gal...
Need for urgent treatment or hospital admission for heart failure Dying from heart problems Jardiance is not used to treattype 1 diabetes. However, it may be used for other reasons in people who have type 1 diabetes, such as to prevent complications if you also haveheart failureorkidney diseas...
It has a relatively long duration of action requiring only once-daily dosing. Patients should be monitored closely for signs and symptoms of ketoacidosis regardless of blood glucose level as empagliflozin may precipitate diabetic ketoacidosis in the absence of hyperglycemia. As its mechanism of action ...
Diabetic cardiomyopathy (DCM) is considered to be a critical contributor to the development of heart failure. Empagliflozin (EMPA), a sodium-glucose cotransporter 2 inhibitor, has been shown to preve...
See the Interactions section for more details. Current and Past Health Conditions. Tell your healthcare provider if you have any of the following. Kidney or liver problems Inflammation of the pancreas (pancreatitis) Gallbladder problems Heart failure Drink alcohol often or in large amounts High ...
Heart FailureUsed to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with heart failure.Current expert guidelines on heart failure recommend guideline-directed medical therapy with a combination of the following drugs to reduce morbidity and mortality: ...
Before initiating GLYXAMBI, patients should be asked about a history of heart failure or other risk factors for heart failure including moderate to severe renal impairment. Instruct patients to contact their healthcare provider as soon as possible if they experience symptoms of heart failure, ...
93 Significantly lower rates were observed for death from cardiovascular causes (3.7% vs. 5.9% in the placebo group; 38% relative risk reduction), hospitalization for heart failure (2.7% and 4.1%, respectively; 35% relative risk reduction), and all-cause mortality (5.7% and 8.3%, ...